Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Cerilliant
Dow
Merck
Colorcon
Federal Trade Commission
Boehringer Ingelheim
Healthtrust
Mallinckrodt

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,722,650

« Back to Dashboard

Which drugs does patent 8,722,650 protect, and when does it expire?

Patent 8,722,650 protects SOLODYN and is included in one NDA.

This patent has thirteen patent family members in ten countries.
Summary for Patent: 8,722,650
Title:Extended-release minocycline dosage forms
Abstract: An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.
Inventor(s): Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Scottsdale, AZ), Newhard; Steven B. (Scottsdale, AZ), Watt; David (Scottsdale, AZ)
Assignee: Medicis Pharmaceutical Corporation (Bridgewater, NJ)
Application Number:12/861,424
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,722,650

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-008 Aug 27, 2010 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF ACNE ➤ Sign Up
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-007 Aug 27, 2010 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF ACNE ➤ Sign Up
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-006 Aug 27, 2010 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF ACNE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,722,650

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,192,615 Method for the treatment of acne and certain dosage forms thereof ➤ Sign Up
7,790,705 Minocycline oral dosage forms for the treatment of acne ➤ Sign Up
7,541,347 Minocycline oral dosage forms for the treatment of acne ➤ Sign Up
8,268,804 Minocycline oral dosage forms for the treatment of acne ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
McKesson
Cantor Fitzgerald
Cerilliant
Queensland Health
Federal Trade Commission
Boehringer Ingelheim
Dow
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.